Form 4: Travere Therapeutics SVP Sells Shares After Option Exercise
Insider Transaction Report
Travere Therapeutics' SVP, Chief Accounting Officer, Sandra Calvin, sold 67,115 shares of common stock at $36.00 after exercising various stock options.
Summary
- Sandra Calvin, SVP, Chief Accounting Officer of Travere Therapeutics, Inc. (TVTX), executed a series of transactions on November 4, 2025.
- These transactions included the exercise of multiple employee stock options to acquire a total of 61,250 shares of common stock.
- The exercise prices for these options ranged from $8.93 to $27.50 per share.
- Concurrently, Ms. Calvin sold 67,115 shares of common stock at a price of $36.00 per share.
- The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on June 10, 2025.
- Following these transactions, Ms. Calvin's direct beneficial ownership in Travere Therapeutics, Inc. stands at 48,545 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While there is insider selling, it was pre-planned under a Rule 10b5-1 plan, which mitigates concerns about opportunistic selling based on non-public information. The officer also retains a significant number of shares.
Positives
- Ms. Calvin realized a profit by exercising stock options at prices significantly lower than the sale price of $36.00 per share.
- The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to new, non-public information.
Negatives
- Ms. Calvin reduced her direct beneficial ownership in the company by 5,865 shares (67,115 sold 61,250 acquired).
- Insider selling, even if pre-planned, can sometimes be perceived negatively by investors as it reduces management's direct equity stake.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may view the reduction in direct beneficial ownership by a key executive with slight caution, although the pre-planned nature of the sale under Rule 10b5-1 mitigates concerns about opportunistic selling.
Key Dates
| Date | Description |
|---|---|
| 2022-01-31 | First anniversary of vesting for a portion of 15,000 stock options. |
| 2023-01-31 | First anniversary of vesting for a portion of 12,500 stock options. |
| 2024-01-31 | First anniversary of vesting for a portion of 6,250 stock options. |
| 2025-06-10 | Date Rule 10b5-1(c) trading plan was adopted. |
| 2025-11-04 | Date of all reported stock option exercises and share sales. |
| 2025-11-05 | Date the Form 4 was signed. |
| 2028-05-10 | Expiration date for 10,000 exercised stock options. |
| 2031-01-21 | Expiration date for 17,500 exercised stock options. |
| 2032-01-31 | Expiration date for 15,000 exercised stock options (2,500 remaining unexercised). |
| 2033-01-31 | Expiration date for 12,500 exercised stock options (7,500 remaining unexercised). |
| 2034-01-31 | Expiration date for 6,250 exercised stock options (18,750 remaining unexercised). |
Recommendation
holdThe filing details a pre-planned insider sale by a senior executive. While a reduction in insider ownership can sometimes be a yellow flag, the execution under a Rule 10b5-1 plan suggests a personal financial planning event rather than a signal about the company's future performance. The executive still retains a substantial number of shares. Therefore, this specific filing alone does not warrant a change in investment thesis, leading to a 'hold' recommendation, pending further fundamental analysis of the company.
Keywords
Travere Therapeutics, TVTX, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Sandra Calvin, SVP Chief Accounting Officer, Rule 10b5-1 Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.